Advanced Oncotherapy (AVO) has announced a £37.4m equity fundraise to bolster its balance sheet as it moves towards completing its next generation proton beam therapy system LIGHT with a 230MeV beam. The company, which is due to go live with the system by the end of this year, said the funds would be raised from…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2026 All rights reserved LaingBuisson
 has announced a £37.4m equity fundraise to bolster its balance sheet as it moves towards completing its next generation proton beam therapy system LIGHT with a 230MeV beam.){kind=link}